SequelSEC

Processa Pharmaceuticals, Inc. PCSA

Pharmaceutical Preparations · CIK 0001533743 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2023-09-30
Operating income
-$2.17M
Fiscal year ended 2023-09-30
Free cash flow
Unavailable
Fiscal year ended 2023-09-30

Processa Pharmaceuticals, Inc. (PCSA) reported revenue of $0 and net income of -$2.08M for the fiscal year ended 2023-09-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Processa Pharmaceuticals, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Processa Pharmaceuticals, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-30
Revenue$0$0$0$0$0$0$0$0$0Unavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$2.17M-$2.71M-$4.11M-$13.07M-$6.06M-$5.17M-$3.23M-$3.37M-$3.11M-$3.46M
Net income-$2.08M-$2.61M-$4.02M-$13.01M-$6.02M-$5.16M-$3.23M-$3.18M-$2.99M-$3.16M
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$2.04MUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 1.35Mshares 1.35Mshares 1.14M-shares 15.19Mshares 16.20Mshares 15.94MUnavailableUnavailableUnavailableUnavailable
Pretax incomeUnavailable-$2.61M-$4.02M-$13.01M-$6.02M-$5.16M-$3.23M-$3.37M-$3.11M-$3.29M
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-$181.75K-$122.44K-$137.17K
Diluted EPS$-1.54$-1.94$-3.53$-33.15$-0.37$-0.32UnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$1.02M$1.03M$2.48M$2.63M$2.92M$2.03M$1.18M$1.30M$1.34M$1.33M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Processa Pharmaceuticals, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-30
Cash & equivalents$6.86M$8.68M$10.74M$6.50M$9.05M$12.06M$14.39M$16.50M$19.09M$20.83M
Total assets$8.08M$10.09M$12.43M$8.62M$18.60M$21.66M$24.30M$26.46M$29.03M$31.14M
Current assets$7.91M$9.90M$12.22M$8.39M$10.89M$13.96M$16.38M$18.33M$20.67M$22.57M
Total liabilities$914.85K$930.74K$2.29M$1.15M$1.36M$1.58M$1.06M$978.40K$1.82M$1.90M
Current liabilities$826.07K$821.41K$2.16M$998.56K$1.19M$1.57M$1.06M$971.02K$1.23M$1.16M
Total equity incl. NCI$7.17M$9.16M$10.14M$7.47M$17.24M$20.08M$23.24M$25.49M$27.21M$29.24M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$346.30K$239.02K$316.71K$327.55K$311.07K$648.10K$316.09K$218.90K$354.98K$287.88K

Cash flow

Processa Pharmaceuticals, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-30
Operating cash flow-$1.76M-$2.06M-$2.11M-$2.50M-$2.97M-$2.33M-$1.80M-$2.73M-$1.55MUnavailable
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Financing cash flow-$52.75K$0$6.35M-$53.60K-$35.25K$0-$300.00K$131.36K-$185.18KUnavailable
Net change in cash-$1.82M-$2.06M$4.24M-$2.55M-$3.01M-$2.33M-$2.10M-$2.60M-$1.74MUnavailable
Stock-based compensation$142.89K$319.12K$341.50K$2.78M$3.21M$2.01M$828.90K$1.12M$1.11M$865.32K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Processa Pharmaceuticals, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-30
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio9.57x12.05x5.65x8.40x9.13x8.89x15.49x18.87x16.85x19.43x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PCSA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-18View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2016-12-31

Difference 4534458 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2015-12-31

Difference 1893102 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.